AstraZeneca Buys Back 210,000 Own Shares To Cancel
17th Jun 2010 08:25
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN), said Thursday that it purchased for cancellation 210,000 ordinary shares at a price of 3065 pence per share. MAIN FACTS: -Upon the cancellation of these shares, the number of shares in issue will be 1,441,169,972. Shares at 0725 GMT down 0.5
Read moreCanadian court reversal for Astra
17th Jun 2010 07:26
The Federal Court of Canada has blocked drugs giant AstraZeneca's attempt to delay the launch of a generic version of Astra's gastrointestinal disease treatment, Nexium. The court dismissed the drug company's request to prohibit the Canadian Minister of Health from issuing a Notice of Compliance (N
Read moreAstraZeneca: Canadian Court Allows NOC On Apotex' Esomeprazole
17th Jun 2010 07:12
LONDON (Dow Jones)--Pharmaceutical giant AstraZeneca PLC (AZN.LN) said Thursday the Federal Court of Canada has dismissed its request to prohibit the Canadian Minister of Health from issuing a Notice of Compliance, or NOC, for the regulatory applications for generic esomeprazole magnesium submitted
Read moreUPDATE: Biocompatibles Shares Up On Move Into Profit
16th Jun 2010 11:00
(Adds analyst comment, share price) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--U.K. medical technology company Biocompatibles International PLC (BII.LN) said Wednesday it will report a profit for the first six months of 2010 following strong sales of its drug-eluting bea
Read moreMARKET TALK: UBS Upgrades European Tech Hardware, Software
16th Jun 2010 09:53
0853 GMT [Dow Jones] UBS upgrades the European ex-UK tech hardware sector to overweight from underweight, given attractive valuations. Says relative earnings momentum is already at a record low, and "it is hard to see it getting much worse." Also upgrades software to overweight from neutral, as a pl
Read moreAstraZeneca Buys Back 310,000 Own Shares To Cancel
16th Jun 2010 08:27
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN), said Wednesday that it purchased for cancellation 310,000 ordinary shares at a price of 3058 pence per share. MAIN FACTS: -Upon the cancellation of these shares, the number of shares in issue will be 1,441,379,972. Shares at 0725 GMT down 23
Read moreCertain Blood-Pressure Drugs Tied To Cancer Risk In Study
14th Jun 2010 13:03
(This article was originally published Sunday.) By Peter Loftus Of DOW JONES NEWSWIRES A new study found that a popular class of anti-hypertension drugs--including those made by Boehringer Ingelheim GmbH, Merck & Co. (MRK) and Novartis AG (NVS, NOVN.VX)--is associated with a modestly in
Read moreCertain Blood-Pressure Drugs Tied To Cancer Risk In Study
13th Jun 2010 23:30
By Peter Loftus Of DOW JONES NEWSWIRES A new study found that a popular class of anti-hypertension drugs--including those made by Boehringer Ingelheim GmbH, Merck & Co. (MRK) and Novartis AG (NVS, NOVN.VX)--is associated with a modestly increased risk of cancer. The researchers cautioned
Read moreN AMERICAN MORNING BRIEFING: Stocks Seen Little Changed
11th Jun 2010 11:25
DJIA Futures 10165.5 +10.5 +0.1% S&P 500 Futures 1082.3 +2.5 +0.2% Nasdaq Futures 1825.1 +4.0 +0.2% Above are as of 0615 ET FTSE 100 5175.2 +42.7 +0.8% Xetra DAX 6065.6 +9.0 +0.2% CAC40 3544.8 +28.1 +0.8% Above are as of 0
Read moreMARKET TALK: BarCap Upgrades AstraZeneca To Overweight
11th Jun 2010 07:28
0628 GMT [Dow Jones] Barclays Capital upgrades AstraZeneca (AZN) to overweight from equalweight and lifts its target price to 3400p from 3300p. "Due diligence around the Crestor US patent litigation leads us to consider the risks sufficiently tolerable for a more positive view of the stock." It says
Read morePRESS RELEASE: Ron Laufer named Senior Managing Director of MedImmune Ventures
10th Jun 2010 13:00
GAITHERSBURG, Md., June 10 /PRNewswire/ -- MedImmune announced today that Ron Laufer, M.D., has been appointed Senior Managing Director of MedImmune Ventures, the company's venture capital arm. Laufer's appointment will strengthen MedImmune's long-term commitment to supporting scientific innovation
Read moreAstraZeneca Buys Back 0.3M Shares At 2912P Each
9th Jun 2010 08:16
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Wednesday it purchased for cancellation 330,000 ordinary shares at a price of 2912 pence per share. -Shares at 0715 GMT up 6.5 pence, or 0.22%, at 2927.5 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected]
Read moreIN THE PIPELINE: Micromet Grabs Immune System In Cancer Fight
8th Jun 2010 16:00
By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Micromet Inc. (MITI) is developing drugs that use an aggressive approach to using the body's own defenses in fighting cancer. Unlike Dendreon Corp.'s (DNDN) recently approved Provenge, which works like a vaccine to stimulate an
Read moreAstraZeneca Buys Back 0.15M Shares At 2910P Per Share
8th Jun 2010 08:28
LONDON (Dow Jones)--AstraZeneca PLC (AZN.LN) said Tuesday it purchased for cancellation 150,000 ordinary shares at a price of 2910 pence per share. -Shares at 0727 GMT down 12.5 pence, or 0.43%, at 2913.5 pence. -By Iain Packham, Dow Jones Newswires; 44-20-7842-9269; [email protected]
Read moreLondon close: Footsie ends up
18th May 2010 16:42
Footsie finished with good gains but edged down from earlier highs after a poor start on Wall Street. Man Group was the best performer on reflection of yesterday's deal to buy GLG for $1.6bn. Inter-dealer broker ICAP was also in demand, ahead of its full year results tomorrow, while mezzanine finan
Read more